Intravitreal bevacizumab in diabetic retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 knobloch lecture

The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevaci-zumab as a preoperative, adjuvant therapy before vitrectomy for prolif-erative diabetic retinopathy. Copyright © 2017 by Asia Pacific Academy of Ophthalmology.

• Fecha de publicación: 2018
• Institución: Universidad del Rosario
• Repositorio: Repositorio EdocUR - U. Rosario
• Idioma: eng
• OAI Identifier: oai:repository.urosario.edu.co:10336/23077
• Acceso en línea: https://doi.org/10.22608/APO.2017466; https://repository.urosario.edu.co/handle/10336/23077
• Palabra clave: Angiogenesis inhibitor; Bevacizumab; Adjuvant chemotherapy; Diabetic retinopathy; Human; Intravitreal drug administration; Macular edema; Preoperative care; Angiogenesis inhibitors; Bevacizumab; Diabetic retinopathy; Humans; Intravitreal injections; Macular edema; Preoperative care; Bevacizumab; Diabetic macular edema; Intravitreal injections; Proliferative diabetic retinopathy; Tractional retinal detachment; adjuvant; Chemotherapy
• License: Abierto (Texto Completo)